SAB Biotherapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $114 | $0 | $263 | $944 |
Gross Profit | 1,799 | -758 | -1,040 | |
EBITDA | -10,538 | -9,304 | -6,220 | -2,964 |
EBIT | -11,323 | -10,271 | -7,242 | -4,949 |
Net Income | -11,394 | -10,349 | -7,335 | -5,025 |
Net Change In Cash | 114 | 0 | 263 | 944 |
Free Cash Flow | -9,014 | -6,392 | -7,839 | -11,046 |
Cash | 8,897 | 9,171 | 17,242 | 14,034 |
Basic Shares | 9,261 | 9,259 | 9,255 | 9,241 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,322 | $2,238 | $23,904 | $60,876 |
Gross Profit | 1,322 | -1,506 | 20,612 | 59,222 |
EBITDA | -42,910 | -38,133 | -15,121 | -11,711 |
EBIT | -34,423 | -41,878 | -18,413 | -11,947 |
Net Income | -34,105 | -42,193 | -18,740 | -17,444 |
Net Change In Cash | 1,322 | 2,238 | 23,904 | 60,876 |
Free Cash Flow | -34,292 | -25,316 | -7,185 | -7,185 |
Cash | 8,897 | 56,566 | 15,046 | 33,206 |
Basic Shares | 9,261 | 5,521 | 4,352 | 2,733 |
Earnings Calls
| Quarter | EPS |
|---|---|
2021-06-30 | -$0.12 |
2021-03-31 | -$0.02 |
2020-12-31 | -$0.02 |
2020-09-30 | $0.15 |
